Avalo (AVTX) is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Avalo’s pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
Avalo Announces Participation in September Investor Conferences
Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates
Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer